Two splice variants derived from the BCL-x gene, proapoptotic Bcl-x(s) and anti-apoptotic Bcl-x(L), are produced via alternative 5 splice site selection within exon 2 of Bcl-x pre-mRNA. In previous studies, our laboratory demonstrated that ceramide regulated this 5 splice site selection, inducing the production of Bcl-x(s) mRNA with a concomitant decrease in Bcl-x(L) correlating with sensitization to chemotherapy (Chalfant, C. E., Rathman, K., Pinkerman, R. L., Wood, R. E., Obeid, L. M., Ogretmen, B., and Hannun, Y. A. (2002) J. Biol. Chem. 277, 12587-12595). We have now identified several possible RNA cis-elements within exon 2 of Bcl-x pre-mRNA by sequence analysis. To study the possible roles of these RNA cis-elements in regulating the alternative 5 splice site selection of Bcl-x pre-mRNA, we developed a BCL-x minigene construct which conferred the same ratio of Bcl-x(L)/Bcl-x(s) mRNA as the endogenous Bcl-x and was responsive to ceramide treatment. Mutagenesis of either a purine-rich splicing enhancer or a pyrimidine tract element within exon 2 induced a change in the ratio of Bcl-x(L)/Bcl-x(s) mRNA from 7 to 1 and 0.23, thereby diminishing the selection of the Bcl-x(L) 5 splice site with a concomitant increase in Bcl-x(s) 5 splice site selection. Furthermore, mutagenesis of these cis-elements abolished the ability of ceramide to affect the 5 splice site selection. In vitro binding assays coupled with competitor studies demonstrated specific binding of RNA trans-activating proteins to these regions. SDS-PAGE analysis of cross-linked RNA transactivating factors with these RNA cis-elements revealed the binding of 215-, 120-, and 30-kDa proteins to the purine-rich element and 120-and 76-kDa proteins to the pyrimidine tract element. In addition, exogenous treatment of A549 cells with ceramide increased the formation of protein complexes with these RNA cis-elements. Therefore, we have identified two ceramide-responsive RNA cis-elements within exon 2 of Bcl-x pre-mRNA, and this is the first report of an RNA cis-element responsive to a bioactive lipid.
Ceramide is an important regulator of various stress responses and growth mechanisms, and the formation of ceramide from the hydrolysis of sphingomyelin or from de novo pathways has been observed in response to agonists such as tumor necrosis factor-␣, ␥-interferon, 1␣,25-dihydroxyvitamin D 3 , interleukin-1, ultraviolet light, heat, chemotherapeutic agents, fatty-acid synthase antigen, and nerve growth factor (1) (2) (3) (4) (5) (6) (7) . Also, the addition of exogenous ceramide or the enhancement of cellular levels of ceramide induces cell differentiation, cell cycle arrest, apoptosis, or cell senescence in various cell types (8 -10) .
The prominent role of ceramide as a regulator of cellular mechanisms necessitated the identification of target molecules. A family of ceramide-regulated enzymes has been identified, ceramide-activated protein phosphatases, which include the serine/threonine-specific protein phosphatases PP1 1 and PP2A (11) (12) (13) (14) . Interestingly, SR proteins, a family of arginine/serinerich domain containing proteins, have been shown to be specific PP1 substrates and are well established regulators of alternative pre-mRNA processing (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . Furthermore, endogenous ceramide has been found recently to modulate the phosphorylation status of SR proteins in a PP1-dependent manner (26) . PP1 also associates with the splice factor, PTB-associated splicing factor (PSF), and the PP1 regulatory subunit, nuclear inhibitor of PP1 (NIPP1), has been demonstrated to co-localize with splicing factors (15, 25, 27, 28) . Finally, dephosphorylation of SR proteins stimulated by PP1 induces alternative 5Ј splice site selection in adeno pre-mRNA in vitro, demonstrating that pre-mRNA splicing events are regulated in a phosphorylationdependent manner (29) . Thus, PP1 plays an important role in regulating mRNA processing.
To this end, our laboratory recently described a pathway linking the generation of ceramide and activation of PP1 to the regulation of the alternative 5Ј splice site selection of Bcl-x pre-mRNA. Ceramide treatment resulted in a decrease in Bclx(L) mRNA with concomitant increase in Bcl-x(s) mRNA in A549 cells. This effect required the generation of endogenous ceramide through the de novo pathway, and more importantly, inhibitors of protein phosphatase-1 abolished the ability of ceramide to affect Bcl-x alternative splicing (30) . Thus, both the phospho-state of SR proteins and Bcl-x 5Ј splice site selection are regulated by the generation of de novo ceramide and subsequent PP1 activation.
The involvement of PP1 and endogenous ceramide in the dephosphorylation of SR proteins and the effects on Bcl-x alternative splicing suggested ceramide regulated the protein-RNA complexes that mediate the 5Ј splice site selection of Bcl-x pre-mRNA. In this study, we identified a purine-rich RNA cis-element that corresponds to an SRp30a-binding site, as well as a polypyrimidine tract site known to bind RNA splice factors, such as PSF, within exon 2 of Bcl-x mRNA. Furthermore, both RNA cis-elements regulated Bcl-x 5Ј splice site selection and were found to be responsive to ceramide.
MATERIALS AND METHODS
Cell Culture-A549 adenocarcinoma cells were grown in 50% RPMI 1640 (Invitrogen) and 50% Dulbecco's modified Eagle's medium (Invitrogen) supplemented with L-glutamine, 10% (v/v) fetal bovine serum (Sigma), 100 units/ml penicillin G sodium (Invitrogen), and 100 g/ml streptomycin sulfate (Invitrogen). Cells were maintained at less than 80% confluency under standard incubator conditions (humidified atmosphere, 95% air, 5% CO 2 , 37°C). For treatments with D-erythro-C 6 ceramide (Matreya) or long chain ceramides (Brain) (Sigma), A549 cells were plated at 4 ϫ 10 5 cells/35-mm plate in the same media. BCL-x Minigene Construct-PCR amplification of Bcl-x genomic sequence was accomplished using Human Genomic DNA (Promega) as template and two separate amplification reactions. The first PCR amplified a 1443-bp sequence of the BCL-x gene containing exon 1, intron 1, exon 2, and the flanking region of intron 2 and utilized the following primers: sense, 5Ј-GCATTCCTCGAGGGCGGATTTGAATGTAGGT-3Ј; antisense, 5Ј-GCATTCGCGGCCGCGAGAGAAGCCCAGGATAGGA-C-3Ј (Integrated DNA Technologies, Inc.). The amplification reaction was carried out for 30 cycles (94°C, 30 s; 68°C, 1.5 min). The second PCR amplified a 477-bp sequence of the BCL-x gene containing the flanking region of intron 2 and partial exon 3 used the following primers: sense, 5Ј-GCATTCGCGGCCGCCCTGACCCTGCCCATCTCGTT-3Ј; antisense, 5Ј-GCATTCAAGCTTACCAGCGGTTGAAGCGTTCCT-3Ј (Integrated DNA Technologies, Inc.). The PCR was carried out for 30 cycles (94°C, 30 s; 56°C, 30 s; 72°C, 40 s). The BCL-x minigene was then constructed in the plasmid, pcDNA 3.1(Ϫ) (Invitrogen), by a twostep process. In step 1, the 477-bp fragment was cloned into the plasmid by using restriction enzymes NotI and HindIII. In step 2, the 1443-bp fragment was cloned into the plasmid by using restriction enzymes XhoI and NotI. For both fragments, inclusion and proper orientation were verified by sequence analysis. The final construct contained a minigene product of 1.92 kb (Fig. 1) .
Transfection-A549 cells were transfected with the BCL-x minigene construct using Superfect reagent (Qiagen Corp.) following the manufacturer's protocol. Briefly, A549 cells were plated at 40 -50% confluency in 6-well tissue culture dishes 24 h prior to transfection. Cells were transfected with 2 g of plasmid mixed with 10 l of Superfect reagent for 4 h. After 24 h, the cells were treated with D-erythro-C 6 ceramide for 16 h and examined for minigene expression by reverse transcription (RT)-PCR.
RT-PCR Assay-Total RNA from A549 cells was isolated with Trizol reagent (Invitrogen). 1 g of A549 total RNA was reverse-transcribed using oligo(dT) and the Superscript II preamplification kit (Invitrogen). 1 l of the reverse transcription reaction was amplified using a specific primer for the pcDNA 3.1 cDNA sequence (5Ј-AAA CTT AAG CTT GGT ACC GAG-3Ј) (Integrated DNA Technologies, Inc.), a specific primer to Bcl-x exon 2 (5Ј-GGA GCT GGT GGT TGA CTT TCT-3Ј) (Integrated DNA Technologies, Inc.), and Platinum TaqDNA polymerase (Invitrogen). Following 25 cycles (94°C, 30 s melt; and 68°C, 1 min anneal/ extension), the PCR was examined by 1.5% agarose gel electrophoresis.
Mutagenesis-The five potential cis-elements within exon 2 of the BCL-x minigene construct were mutated to produce replacement mutants using the Chameleon mutagenesis kit (Stratagene). All mutants were sequenced to verify mutations and control for abnormalities in cloning at the MUSC core facility.
Nuclear Extracts-Nuclear extracts were prepared from both HeLa and A549 lung adenocarcinoma cells according to the method of Dignam et al. (31) . Protein concentrations were determined by a modification of the Bradford method using the Bio-Rad protein assay reagent (Bio-Rad).
Electromobility Shift Assay-The following sequences were used for fluorescein-tagged RNA oligonucleotides: CRCE 1, r(5Ј-Fl-GAGGGAG-GCAGGCGACGAC), and CRCE 2, r(5Ј-Fl-CCUUUUUCUCCUUC) (Qiagen-Xergon). RNA binding reactions were performed in a final volume of 25 l containing 400 ng of CRCE 1 or CRCE 2 fluoresceinoligonucleotide, 50 g of nuclear protein extract, 40 units of RNAsin, and 11.3 g of tRNAs in buffer composed of 10 mM HEPES, 1 mM dithiothreitol, 120 mM KCl, 3 mM MgCl 2 , and 5% glycerol. The reaction mixtures were incubated at 4°C for 20 min followed by 5 min of UV cross-linking. Samples were loaded on a 5% TBE Criterion TM Precast Gel (Bio-Rad) for electrophoretic separation of RNA-protein(s) complexes for 1.5 h at 115 V at 4°C. The gel was then scanned using Molecular Imager® FX (Bio-Rad) with a 488 nm EX (530 nm BP) laser.
SDS-PAGE Analysis-Following the same procedures for the binding reactions described for electromobility shift assay (EMSA) (above), samples were boiled in Laemmli buffer for 10 min and then loaded on a denaturing, 15% Tris-HCl Criterion TM Precast Gel for determination of the molecular weights of the separated RNA-protein(s) complexes.
Competition Studies-Competition studies were performed using 100-fold molar excess of either specific or nonspecific oligonucleotide competitor. The following competitor sequences were used: nonspecific competitor, 5Ј-GAA UUC GCA CGU UA-3Ј; CRCE 1-specific competitor, 5Ј-GAG GGA GGC AGG CGA CGA-3Ј; and CRCE 2-specific competitor, 5Ј-CCU UUU UCU CCU UC-3Ј.
RESULTS

Identification of RNA cis-Elements in Exon 2 of the BCL-x
Gene-Previously, our laboratory reported that the alternative 5Ј splice site selection of Bcl-x was regulated by ceramide, correlating with the phosphorylation status of SR proteins (26, 30) . Furthermore, the phosphorylation status of SR proteins has been shown to regulate 5Ј splice site selection (29) . Therefore, exon 2 of the BCL-x gene was examined for sequences known to bind specific SR proteins as well as for other possible RNA cis-elements (32) . One possible SRp30a-binding site (site 1, position 625-638 bp from Bcl-x intron 2), two possible SRp40-binding sites (sites 2 and 3, positions 462-475 and 348 -360 bp, respectively, from Bcl-x intron 2), a purine-rich exon splicing enhancer (site 4, position 277-295 bp from Bcl-x intron 2), and one pyrimidine tract site (site 5, position 127-140 bp from Bcl-x intron 2) were found within exon 2 ( Fig. 1,  panel A) .
To determine whether these RNA cis-elements played a role in regulating the alternative 5Ј splice site selection of Bcl-x pre-mRNA, a functional minigene was constructed by ligation of two DNA fragments of the BCL-x gene containing exon 1, intron 1, exon 2 (containing all five potential cis-elements), part of intron 2, and part of exon 3 ( Fig. 1, panel B) . These possible RNA cis-elements were modified in the minigene construct by replacement mutagenesis (Fig. 1, panel A) . By using this method, the sequences were mutated without affecting the distances between splice sites within exon 2, and thus, reducing the possibility of artifactual results. Mutation of the purinerich RNA cis-element (ceramide-responsive RNA cis-element 1, CRCE 1) changed the ratio of Bcl-x(L)/Bcl-x(s) mRNA from 7 to 1. Mutation of the pyrimidine tract (CRCE 2) between the Bcl-x(s) and Bcl-x(L) 5Ј splice sites significantly blocked the production of minigene BCL-x(L) mRNA, changing the ratio from 7 to 0.23. Furthermore, ceramide did not affect the alternative splicing of both these Bcl-x mutants (Fig. 1, panel C) . Mutation of the other three cis-elements within exon 2 had no effect on the basal and ceramide-induced RNA processing of Bcl-x pre-mRNA (data not shown). Therefore, two regulatory sites for Bcl-x 5Ј splice site selection were identified within exon 2, and these sites act as either possible enhancers of the Bcl-x(L) 5Ј splice site or silencers of the Bcl-x(s) 5Ј splice site.
RNA trans-Activating Factors Specifically Bind the Ceramide-responsive cis-Elements-Once the potential CRCEs were identified, the ability of RNA trans-activating factors to bind these RNA cis-elements was examined. Binding assays using nuclear extracts from A549 and HeLa cells and a fluoresceintagged oligonucleotide sequence for CRCE 1 or CRCE 2 were UV cross-linked and analyzed by an EMSA. Both nuclear extracts retarded the mobility of the oligonucleotides, producing several protein-RNA complexes by non-denaturing gel electrophoresis (data not shown). The specificity of these complex formations in A549 nuclear extracts was confirmed by the use of specific or nonspecific competitor oligonucleotides and denaturing gel analysis. The approximate molecular weights of the specific protein(s) complexed to CRCE 1 were determined to be 215, 120, and 30 kDa, and binding of these proteins to CRCE 1 was eradicated upon the addition of a 100-fold specific competitor (Fig. 2, panel A) . Similar analysis of CRCE 2 revealed specific protein(s) complexes of 120 and 76 kDa that, as with CRCE 1, were eradicated upon the addition of a 100-fold specific competitor (Fig. 2, panel B) . These results demonstrate that RNA trans-activating factors bind/complex specifically with the CRCEs. Similar results were obtained using nuclear 
extracts from HeLa cells (data not shown).
Ceramide Regulates the Binding of RNA trans-Activating Factors to the CRCEs-Exposure of A549 cells to D-erythro-C 6 ceramide solubilized in ethanol (EtOH) induces the production of endogenous ceramide after 12 h (data not shown). To determine whether the binding of RNA trans-activating factors to the CRCEs is responsive to ceramide, A549 cells were treated with exogenous ceramide at a concentration (20 M) and time (Ͼ12 h) that induces de novo ceramide generation and alternative 5Ј splice site selection of the Bcl-x exon 2 (26, 30, 33) . Nuclear extracts from A549 cells treated with 20 M cell-permeable D-erythro-C 6 ceramide for 12 and 30 h demonstrated an increase in protein-oligonucleotide complex formation for CRCE 1 and CRCE 2 as determined by EMSA (data not shown). An increase in complex formation was also observed for the 215-, 120-, and 30-kDa protein(s) complexes to CRCE 1 at both 12 and 30 h of ceramide treatment (Fig. 3, panel A) . Similarly, an increase in complex formation at both 12 and 30 h of ceramide treatment was also observed for CRCE 2 bound to protein(s) having molecular weights of 120 and 76 kDa (Fig. 3,  panel B) . Thus, exogenous ceramide at treatment points that induce the activation of the Bcl-x(s) 5Ј splice site and induce the production of endogenous long chain ceramides also induce the stable formation of protein complexes with the CRCEs.
Because the stable formation of protein complexes to the CRCEs correlates with the conversion of short chain ceramides to long chain ceramides, we examined whether the exogenous addition of long chain (natural) ceramides induces a more rapid formation of protein-CRCE complexes. Acute treatment of A549 cells with brain ceramides (10 M) induced a significant increase in the protein-CRCE 1 and protein-CRCE 2 complexes as early as 30 min (Fig. 4, panels A and B) . Thus, long chain (natural) ceramides induce a rapid increase in the complex formation of proteins to the CRCEs. DISCUSSION Previously, our laboratory reported that ceramide induces, via alternative splicing, the expression of the pro-apoptotic splice variant Bcl-x(s), with a concomitant loss in the antiapoptotic splice variant, Bcl-x(L) (30) . In this study, two RNA cis-elements have been identified that regulate the alternative 5Ј splice site selection of Bcl-x pre-mRNA. Furthermore, the protein-RNA interaction of these RNA cis-elements was regulated by ceramide, and we therefore designated the RNA sequences as ceramide-responsive RNA cis-elements (CRCEs). These findings are important for several reasons. First, they provide a mechanistic understanding of the regulation of Bcl-x alternative splicing. Second, a direct link between ceramide, SR proteins, and the regulation of Bcl-x RNA processing has now been substantiated. Finally, this is the first identification of RNA-protein interactions responsive to a bioactive lipid.
Many reports in the literature demonstrate that the physiological fate of the cell can be determined by the ratio of antiapoptotic Bcl-x(L) to pro-apoptotic Bcl-x(s), and induction of pro-apoptotic Bcl-x(s) sensitizes cells to chemotherapeutic agents (35) (36) (37) . This has been demonstrated by specifically redirecting the alternative 5Ј splice site selection of Bcl-x to increase the expression of Bcl-x(s) at the expense of the levels of Bcl-x(L) (36, 37) . In recent studies, Bcl-x alternative splicing was specifically modulated using an antisense oligonucleotide specific for Bcl-x pre-mRNA at a site surrounding the Bcl-x(L) 5Ј splice site (36, 37) . Hybridization of this oligonucleotide to Bcl-x pre-mRNA induced an increase in the expression of Bclx(s) and a decrease in the expression of Bcl-x(L) resulting in sensitization of the cells to chemotherapeutic agents and eventually inducing apoptosis after long term exposure (Ͼ48 h) (36, 37) . Mechanistically, the study by Taylor et al. (36) demon-FIG. 2 . The binding specificity of RNA trans-activating factors to the CRCEs. Nuclear extracts were prepared from A549 cells and subjected to EMSA binding conditions by reacting with labeled CRCE 1 or CRCE 2 followed by UV cross-linking. 100 ϫ of non-labeled nonspecific competitor (NSC) or specific competitor (SC) was included in the binding assay to show specificity of RNA-protein complexes. Binding analysis was performed by denaturing gel electrophoresis (panels A and B). Closed arrows indicate specific RNA-protein(s) complexes, and open arrows indicate nonspecific RNA-protein(s) complexes. Each control was run on the same gel as the corresponding data; however, where applicable, control lanes were affixed to the left-most region of each gel for the ease of the reader. The data are representative of six separate determinations on six separate occasions. strated that inhibition of the Bcl-x(L) 5Ј splice site led to the default activation of the Bcl-x(s) splice site. Based on the early findings of Krainer and co-workers (38) , this suggests that the Bcl-x(L) 5Ј splice site (downstream) binds the U1 snRNP with high affinity. This high affinity binding of the U1 snRNP is associated with protein-protein interactions of the U1-70-kDa snRNP with RNA trans-activating factors, such as SR proteins. Our results are consistent with these previous findings. We demonstrated that the mutagenesis of CRCE 1 or CRCE 2 induces a decrease in Bcl-x(L) mRNA with concomitant increase in Bcl-x(s). This suggests that both CRCEs function as binding sites for RNA trans-activating factors that enhance the binding of the U1 snRNP to the Bcl-x(L) 5Ј splice site. As with the findings of Taylor et al. (36) , this suggests that the Bcl-x(s) 5Ј splice site is activated if binding of the U1-70-kDa snRNP to the Bcl-x(L) 5Ј splice site is disrupted.
This study also "sheds light" onto the mechanism by which ceramide affects the 5Ј splice site selection of Bcl-x pre-mRNA. This is due to the finding that a purine-rich RNA cis-element (CRCE 1) binds a 30-kDa protein, and ceramide increases the interaction of this protein with CRCE 1. The 30-kDa protein, SRp30a (ASF/SF2), is well known to bind purine-rich RNA cis-elements (exon splicing enhancers) and regulate alternative 5Ј splice selection. Therefore, the observation that CRCE 1 forms a complex with an ϳ30-kDa protein is consistent with our previous findings showing that the dephosphorylation of SR proteins (e.g. SRp30a) in response to ceramide correlated with the regulation of alternative 5Ј splice site selection of Bcl-x pre-mRNA. Thus, a direct link between the generation of ceramide, PP1 activation, SRp30 dephosphorylation, complex formation to CRCE 1, and subsequent Bcl-x alternative splicing may be inferred (Fig. 4) . Our observation that the pyrimidine tract element, CRCE 2, is also responsive to ceramide for complex formation correlates well with this proposed paradigm. This is due to the observation that CRCE 2 binds to an ϳ120-kDa complex that may correspond to the polypyrimidine tractbinding protein-associated splicing factor (PSF). PSF contains an N-terminal binding site for PP1, a ceramide-activated protein phosphatase and the target enzyme of ceramide responsible for dephosphorylating SR proteins (28) . Furthermore, a study by Zipori and co-workers (39) demonstrated that the phospho-status of PSF can change its protein binding capabilities to associate with U1-70-kDa protein and SR proteins during apoptosis. Thus, one can hypothesize that a PSF-PP1 complex bound to CRCE 2 can interact with SR proteins bound to CRCE 1, and this interaction may be regulated by the activity of PP1 in response to ceramide. The observation that a 120-kDa complex is observed for both CRCE 1 and CRCE 2 substantiates this possibility. Furthermore, the regulation of Bcl-x 5Ј splice site selection by ceramide is PP1-dependent (30) . Thus, this study suggests a possible regulatory role for SR proteins and a PSF-PP1 complex in the alternative splicing of Bcl-x.
On the other hand, ceramide may indirectly regulate the formation of protein-RNA complexes at CRCE 1 and CRCE 2. Several studies in the literature (22, 34, 40 ) demonstrate that changes in the level of expression of SR proteins in response to growth factors and cellular proliferation can also regulate the alternative splicing of specific pre-mRNAs. For example, Taub and co-workers (40) first cloned the SR protein, SRp40/HRS, using a subtractive cDNA library in a model of regenerating rat liver responsive to insulin. Subsequently, they showed that this increase in the expression of SRp40 in response to insulin was required for the inclusion of exon EIIIB of the fibronectin gene (22) . Krainer and co-workers (34) demonstrated that increased levels of SRp30a during T-cell activation correlated with changes in the alternative splicing patterns of CD44 and CD45 pre-mRNA. Although the rapid effect of long chain ceramides on the complex formation at CRCE 1 and 2 suggests a mechanism via the direct activation of PP1, further studies are warranted in determining whether the effect of ceramide on the 5Ј splice site selection of Bcl-x pre-mRNA is through an indirect mechanism.
In conclusion, these results demonstrate the identification of two ceramide-responsive RNA cis-elements that may function to control Bcl-x alternative splicing in response to apoptotic stimuli and thereby increase the sensitivity of a cell to undergo apoptosis. This is the first report of a lipid-responsive RNA cis-element, and these results also demonstrate a novel role for ceramide in the regulation of complex formation of RNA trans-activating factors to these RNA cis-elements. This mechanism of regulation may have direct relevance to drug resistance and chemotherapeutic sensitivity because specific regulation of the alternative splicing of Bcl-x is linked to the sensitization of cells to chemotherapy, giving rise to a new target for anti-cancer therapies.
